Back to catalogue
№ 143 27 filings · 2021-09-21 → 2026-09-21

CRANEWARE PLC

CRW
Health Care Share price 1,108p Market cap £375m Overall fit 505 /1000

Vertical healthcare SaaS with embedded AI product and Microsoft partnership at a de-rated ~12x adj P/E, near-net-cash and high recurring revenue — decent operating leverage and fair valuation, but AI is not yet a demonstrable revenue driver and near-term is fogged by cyber and 340B uncertainty, limiting fit to the investor's high-conviction band.

Fair value range 950p–1,350p Mid case · £513m
Absolute upside +37% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • clean SaaS disclosure and APM reconciliations
  • $185m contracted ARR anchors a valuation floor
  • multiple valuation methods converge on current price
Limits the call
  • cyber incident financial impact unquantified
  • 340B regulatory trajectory drives near-term revenue outcomes
Methodology

12-15x FY26 adj diluted EPS cross-checked with EV/adj-EBITDA 9-11x

In one line · bull case

Vertical healthcare SaaS with embedded AI and 40% US hospital footprint, de-rated 57% in twelve months to a ~12x adj P/E on a business with high recurring revenue, near-net-cash and free 340B optionality — fair-to-modestly-undervalued for patient capital.

In one line · biggest risk

The July 2026 cyber incident and unresolved 340B regulatory framework create a wide near-term earnings range that could delay any re-rating well beyond FY28.

Drivers
AI beneficiary 50 /100
Vertical SaaS with embedded AI (Trisus Assist), proprietary healthcare dataset and Microsoft Frontier partnership, but revenue uplift from AI still small and mostly reinforces retention rather than expansion.
Operating leverage 65 /100
84% gross margin, mostly fixed R&D and central costs, but EBITDA margin already 33% so incremental leverage on a revenue beat is meaningful but not multi-baggering.
Earnings vs expectations 30 /100
Three years of beats followed by a decisive FY26 miss and a full FY27 reset — recent track record is weakening.
Growth momentum 25 /100
Revenue flat, ARR flat, NRR 100%, and FY27 explicitly guided to no growth off ARR base — momentum decisively down.
Moat 65 /100
21-year average customer tenure, >90% retention across measures, deep workflow integration and proprietary data — but the moat did not prevent the 340B stall.
Earnings quality 60 /100
98% cash conversion of adj EBITDA and clean recurring-revenue disclosure, offset by material intangible amortisation from Sentry that widens the gap between statutory and adjusted EPS.
Management quality 55 /100
18-year CEO tenure with consistent delivery until FY26; timing of the $25m buyback with hindsight was poor.
Cyclicality 25 /100
Long-duration subscription revenue selling into non-cyclical US hospital demand; low cyclicality.
Leverage 20 /100
Cash $54.8m vs bank debt $43.5m — effectively net cash of ~$11m; fortress-lite balance sheet.
Value-trap signals · 4
  • 340B rebate licence revenue deferred pending regulator
  • NRR sequential drop 107% to 100%
  • $25m share buyback funded with debt drawn near local price high
  • post-period cyber incident with unquantified financial tail

CRANEWARE PLC (CRW) — Investment Research Note

Executive summary

Craneware is a UK-listed (AIM) vertical SaaS provider of financial performance, revenue-integrity and 340B-pharmacy software to US hospitals, serving c.40% of registered US hospitals via its cloud Trisus platform (which also embeds a Microsoft/OpenAI-based AI assistant, Trisus Assist). The operating trajectory across FY22–FY26 has moved from post-Sentry integration and mid-single-digit growth, to a step-up to 9% revenue growth and 32% EBITDA margins in FY25, then a stall in FY26 (revenue flat at $206m, NRR down to 100% from 107%) as 340B regulatory ambiguity paralysed customer purchasing. The single most important point for valuation today is that the stock has already de-rated ~57% over 12 months to a ~12× adjusted P/E on a business with $185m of contracted ARR, 90%+ retention, 98% cash conversion, and near-net-cash balance sheet — so the debate is whether the FY26 stall + the July 2026 cyber incident are transitory (fair value) or structural (still expensive on a broken thesis).

Fair value estimate

  • Methodology: primary — 12–15× FY26 adjusted diluted EPS of 115.6¢ (≈86p at $1.34/£); cross-checked against EV/adj-EBITDA of 9–11× on $67m EBITDA.
  • Assumptions: FY27 revenue reset to ARR of ~$185m (per company 2026-09-21 FY26 finals); adjusted EBITDA margin held ≥30% via cost review; effective tax rate ~24%; £/$ ~1.32; FY28 return to low- to mid-single-digit growth as 340B tailwinds build. No credit given to Trisus OneLink upside beyond current customer discussions.
  • Fair-value range: 950p – 1,350p per share, implying market cap of ~£420m – £600m, with midpoint ~1,150p (£513m).
  • Current disclosed market cap: £459.5m (share price 1,029.88p).
  • Absolute upside to midpoint: ~+12% (view: fair, with modest upside).

Sector context

  • Sector classification: Health Care (ICB Super-Sector Health Care) — but functionally healthcare IT / vertical SaaS, closer in economics to enterprise software than to hospitals or pharma.
  • Quality profile vs. sector peers: quality above typical Health Care peers (SaaS gross margin 84%, EBITDA margin 33%, ~85% recurring revenue, 21-year average customer tenure, near-net-cash balance sheet); growth in line to slightly below current cohort peers; leverage well below.
  • Listed peers: Waystar (WAY), R1 RCM (RCM), Definitive Healthcare (DH), HealthStream (HSTM), Model N (MODN, pre-take-private). Alfa Financial Software or Kainos are the nearest UK-listed vertical-SaaS comparables by profile, though different end-markets.

Investment thesis (3 bullets)

  • Deep, high-retention installed base with genuine AI-adjacent optionality. ~40% of US hospitals, top-10 <30% of ARR, no customer >8% of ARR, ≥90% retention across all measures, 21-yr avg tenure; Trisus Assist AI agent now used by 400+ customers on Microsoft Azure, with two AI extensions (Labour Productivity, Reimbursement Intelligence) launched in H2 FY26 2026-09-21 FY26 finals. Proprietary data (200m+ patient encounters) plus Microsoft Frontier partner status is the picks-and-shovels angle for the investor's AI thesis.
  • Balance-sheet strength allows patience through the reset. $54.8m cash, $43.5m bank debt (post $25m buyback), $56m undrawn RCF, $100m accordion, 98% operating cash conversion, all covenants met, going-concern comfortable even under severe downside 2026-09-21 FY26 finals. Board still funded 32p total dividend for FY26.
  • 340B optionality is real and free at current price. Company has launched Trisus OneLink – Medication ahead of the HRSA rebate pilot restart (1 Jan 2027) and reports rising enquiries; FY27 guidance explicitly excludes any 340B tailwind 2026-09-21 FY26 finals. If the rebate model scales, both new subscription and transaction revenue accrue to Craneware's existing hospital touch-points.

Key risks (3 bullets)

  • Cyber incident financial tail is unquantified. Data exfiltration confirmed on 20 July 2026 including customer, partner and employee records; ICO and FBI notified; investigation, regulatory fines, notification costs, litigation and insurance recovery all unresolved 2026-09-21 FY26 finals. Management resetting FY27 revenue partly reflects this uncertainty.
  • 340B regulatory regime remains unsettled. FY26 stall was principally 340B: customers could not realise Shelter opportunities, rebate-model licences signed but deferred, transaction revenue slowed 2026-07-03 FY26 trading update. The rebate pilot could be re-postponed, expanded, or replaced — timing risk to the recovery thesis is high.
  • NRR fell from 107% to 100% and revenue miss is a first for management. After an 18-year public track record of growth, FY26 was materially below Board expectations even before the cyber event 2026-07-03 FY26 trading update; 2026-09-21 FY26 finals. Execution premium the shares historically enjoyed has been damaged.

Operating leverage

Craneware's cost base is dominated by fixed R&D and platform costs (development spend $59.6m, or 29% of revenue) and largely fixed customer-facing headcount; direct cost of sales (sales commissions, professional-services delivery, transaction-service delivery) is only $33m or 16% of revenue at 84% gross margin 2026-09-21 FY26 finals. The FY26 outturn is a live case study: revenue was flat but the mix shifted (more transaction revenue with lower gross margin) and gross margin compressed 300bp, yet the net operating expense line fell $8.3m via disciplined cost control, delivering adjusted EBITDA growth of 3% on flat revenue and margin expansion to 33%. That implies incremental stripped-out opex was negative; on a normalised basis with revenue upside, incremental contribution margin on SaaS revenue at current scale is plausibly 60–70%. A 10–20% revenue beat over the FY27 reset (say $185m → $205–222m) with cost base already sized down could plausibly add $12–25m to EBITDA — i.e., 20–40% EBITDA uplift, not the 2× "multiple of profit" ideal the investor wants. So genuine operating leverage exists but is second-tier rather than best-in-class, because R&D is already lean and the business is already at 33% EBITDA margins.

Value-trap signals

  • 340B rebate revenue explicitly deferred and unable to be recognised — a real, disclosed value contingent on regulatory outcome the company doesn't control 2026-03-02 H1 FY26 results; 2026-09-21 FY26 finals.
  • NRR sequential deterioration from 107% (FY25) to 100% (FY26) is the first weakening of this metric in years 2026-09-21 FY26 finals.
  • Bank debt increased $16m to fund the $25m buyback that was announced at H1 FY26 when management was still confident of double-digit growth — capital allocation timing was poor with hindsight (buyback average price meaningfully above current market) 2026-03-02 H1 FY26 results.
  • Cyber incident is real, disclosed, and financially open-ended. Not fatal but genuinely value-trap-adjacent for a business whose product is trust-in-data.

Earnings vs. expectations

  • FY22 (Sept 2022): Revenue $165.5m, EBITDA $51.8m — 30% margin target achieved ahead of schedule post-Sentry 2022-09-20 FY22 finals. Beat.
  • FY23 (Sept 2023): Revenue $174.0m (~5% growth), EBITDA $54.9m — professional services revenue soft due to post-COVID hospital staffing, but overall in line 2023-09-05 FY23 finals. In line to slight miss on professional services.
  • FY24 (Sept 2024): Revenue $189.3m (+9%), EBITDA $58.3m (+6%) — above market expectations per July 2024 trading update 2024-07-18 FY24 trading update. Beat.
  • FY25 (Sept 2025): Revenue $205.7m (+9%), EBITDA $65.3m — profitability ahead of consensus 2025-07-16 FY25 trading update. Beat.
  • FY26 (Sept 2026): H1 FY26 in line with market (interim beat). July 2026 trading update materially below market: revenue $205–208m and EBITDA $65–67m vs. guidance for continued double-digit growth 2026-07-03 FY26 trading update. Confirmed Sept 2026 2026-09-21 FY26 finals. Material miss. Pattern: three years of beats, then a decisive miss in FY26 caused by 340B market dislocation and slower Shelter conversion. Management guidance history is credible until FY26 — the current reset to ARR-equivalent is deliberately prudent.

Conviction

3 — moderate. Anchors: clean, well-audited IFRS reporting with clear APM reconciliations; recurring revenue base of $185m provides a robust valuation floor; multiple methodologies (P/E, EV/EBITDA, FCF yield) converge on a fair-to-slightly-cheap read on current price; long, high-quality track record of disclosure. Caveats: the FY27 revenue floor and the timing/scale of 340B recovery are genuinely unknown, and the cyber incident's ultimate cost cannot yet be quantified — both meaningfully widen any fair-value range and prevent a conviction-4/5.

Filings consulted · 39

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-21Fy26 Final Results2026-09-21_9780780_fy26-final-results.md1.00
  2. 2026-07-03Fy26 Trading Update2026-07-03_9650668_fy26-trading-update.md0.85
  3. 2026-03-04Director 039 S Acquisition OF Shares2026-03-04_9456977_director-039-s-acquisition-of-shares.md0.64
  4. 2026-03-02Fy26 Interim Results2026-03-02_9452145_fy26-interim-results.md0.77
  5. 2026-01-20H1 Fy26 Trading Update And Notice OF Results2026-01-20_9367658_h1-fy26-trading-update-and-notice-of-results.md0.72
  6. 2025-11-21Result OF Agm2025-11-21_9250001_result-of-agm.md0.26
  7. 2025-11-21Agm Statement And Board Changes2025-11-21_9248226_agm-statement-and-board-changes.md0.34
  8. 2025-10-22Annual Report Notice OF Agm Directorate Change2025-10-22_9188009_annual-report-notice-of-agm-directorate-change.md0.81
  9. 2025-09-15Fy25 Final Results2025-09-15_9106955_fy25-final-results.md0.65
  10. 2025-08-20Result OF Agm2025-08-20_9066395_result-of-agm.md0.20
  11. 2025-07-16Fy25 Trading Update2025-07-16_8981215_fy25-trading-update.md0.55
  12. 2025-03-11Fy25 Interim Results2025-03-11_8772293_fy25-interim-results.md0.58
  13. 2025-01-13H1 Fy25 Trading Update2025-01-13_8684202_h1-fy25-trading-update.md0.55
  14. 2024-11-13Result OF Agm2024-11-13_8548094_result-of-agm.md0.20
  15. 2024-11-13Agm Statement And Board Changes2024-11-13_8546242_agm-statement-and-board-changes.md0.26
  16. 2024-10-16Posting OF Annual Report And Notice OF Agm2024-10-16_8490562_posting-of-annual-report-and-notice-of-agm.md0.62
  17. 2024-09-03Fy24 Final Results2024-09-03_8396015_fy24-final-results.md0.45
  18. 2024-07-18Fy24 Trading Update And Notice OF Results2024-07-18_8317424_fy24-trading-update-and-notice-of-results.md0.38
  19. 2024-03-04Interim Results2024-03-04_8067483_interim-results.md0.41
  20. 2024-01-17Trading Update And Notice OF Results2024-01-17_7992463_trading-update-and-notice-of-results.md0.38
  21. 2023-11-16Result OF Agm2023-11-16_7886560_result-of-agm.md0.14
  22. 2023-11-16Agm Statement2023-11-16_7884398_agm-statement.md0.18
  23. 2023-10-17Posting OF Annual Report And Notice OF Agm2023-10-17_7822474_posting-of-annual-report-and-notice-of-agm.md0.43
  24. 2023-09-05Final Results2023-09-05_7735263_final-results.md0.25
  25. 2023-07-17Fy23 Trading Update And Notice OF Results2023-07-17_7635562_fy23-trading-update-and-notice-of-results.md0.21
  26. 2023-03-06Interim Results2023-03-06_7323674_interim-results.md0.23
  27. 2023-01-19Trading Update And Notice OF Results2023-01-19_7469619_trading-update-and-notice-of-results.md0.21
  28. 2022-11-15Result OF Agm2022-11-15_7373840_result-of-agm.md0.07
  29. 2022-11-15Agm Statement And Board Appointment2022-11-15_7372275_agm-statement-and-board-appointment.md0.10
  30. 2022-10-14Posting OF Annual Report And Notice OF Agm2022-10-14_7349126_posting-of-annual-report-and-notice-of-agm.md0.24
  31. 2022-09-20Final Results2022-09-20_7369421_final-results.md0.25
  32. 2022-09-14Change OF Date OF Final Results2022-09-14_7315825_change-of-date-of-final-results.md0.25
  33. 2022-07-26Fy22 Trading Update And Notice OF Results2022-07-26_7136127_fy22-trading-update-and-notice-of-results.md0.21
  34. 2022-03-14Interim Results2022-03-14_6896717_interim-results.md0.23
  35. 2022-01-31Trading Update And Notice OF Results2022-01-31_7000279_trading-update-and-notice-of-results.md0.21
  36. 2021-11-16Result OF Agm2021-11-16_6788325_result-of-agm.md0.07
  37. 2021-11-16Agm Statement And Integration Update2021-11-16_6739486_agm-statement-and-integration-update.md0.10
  38. 2021-10-19Posting OF Annual Report And Notice OF Agm2021-10-19_6816763_posting-of-annual-report-and-notice-of-agm.md0.24
  39. 2021-09-21Final Results2021-09-21_6512425_final-results.md0.10

This research note was authored by a large language model after reading 27 regulatory filings published between 2021-09-21 and 2026-09-21. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.